Literature DB >> 24891623

Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease.

Nathaniel R Smilowitz1, Robert Donnino1, Arthur Schwartzbard2.   

Abstract

Entities:  

Keywords:  cardiovascular diseases; diabetes mellitus; obesity; pharmaceutical preparations; prevention & control

Mesh：

Substances：

Year:  2014        PMID： 24891623     DOI： 10.1161/CIRCULATIONAHA.113.006985

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  11 in total

Review 1.  A Plethora of GLP-1 Agonists: Decisions About What to Use and When.

Authors:  Susan L Samson; Alan J Garber
Journal:  Curr Diab Rep       Date:  2016-12       Impact factor: 4.810

2.  Oleuropein, a component of extra virgin olive oil, lowers postprandial glycaemia in healthy subjects.

Authors:  Roberto Carnevale; Romano Silvestri; Lorenzo Loffredo; Marta Novo; Vittoria Cammisotto; Valentina Castellani; Simona Bartimoccia; Cristina Nocella; Francesco Violi
Journal:  Br J Clin Pharmacol       Date:  2018-05-02       Impact factor: 4.335

Review 3.  Gut-Brain Communication in Parkinson's Disease: Enteroendocrine Regulation by GLP-1.

Authors:  Richard A Manfready; Christopher B Forsyth; Robin M Voigt; Deborah A Hall; Christopher G Goetz; Ali Keshavarzian
Journal:  Curr Neurol Neurosci Rep       Date:  2022-05-28       Impact factor: 5.081

Review 4.  The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review.

Authors:  Jonathan D Newman; Anish K Vani; Jose O Aleman; Howard S Weintraub; Jeffrey S Berger; Arthur Z Schwartzbard
Journal:  J Am Coll Cardiol       Date:  2018-10-09       Impact factor: 24.094

Review 5.  Safety and tolerability of new-generation anti-obesity medications: a narrative review.

Authors:  Dhiren K Patel; Fatima Cody Stanford
Journal:  Postgrad Med       Date:  2018-02-08       Impact factor: 3.840

6.  Extra virgin olive oil use is associated with improved post-prandial blood glucose and LDL cholesterol in healthy subjects.

Authors:  F Violi; L Loffredo; P Pignatelli; F Angelico; S Bartimoccia; C Nocella; R Cangemi; A Petruccioli; R Monticolo; D Pastori; R Carnevale
Journal:  Nutr Diabetes       Date:  2015-07-20       Impact factor: 5.097

Review 7.  A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes.

Authors:  Irene Romera; Ana Cebrián-Cuenca; Fernando Álvarez-Guisasola; Fernando Gomez-Peralta; Jesús Reviriego
Journal:  Diabetes Ther       Date:  2018-11-30       Impact factor: 2.945

8.  Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes.

Authors:  Tracey G Simon; Elisabetta Patorno; Sebastian Schneeweiss
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-10       Impact factor: 13.576

Review 9.  Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.

Authors:  Philip A Levin; Hiep Nguyen; Eric T Wittbrodt; Seoyoung C Kim
Journal:  Diabetes Metab Syndr Obes       Date:  2017-04-04       Impact factor: 3.168

10.  A Pilot Screening of Agro-Food Waste Products as Sources of Nutraceutical Formulations to Improve Simulated Postprandial Glycaemia and Insulinaemia in Healthy Subjects.

Authors:  Gian Carlo Tenore; Domenico Caruso; Maria D'Avino; Giuseppe Buonomo; Giuseppe Caruso; Roberto Ciampaglia; Elisabetta Schiano; Maria Maisto; Giuseppe Annunziata; Ettore Novellino
Journal:  Nutrients       Date:  2020-05-01       Impact factor: 5.717
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.